Insider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells 4,342 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) EVP Jakob Dupont sold 4,342 shares of Atara Biotherapeutics stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $19,495.58. Following the sale, the executive vice president now directly owns 154,540 shares in the company, valued at approximately $693,884.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Atara Biotherapeutics Stock Performance

NASDAQ:ATRA opened at $4.27 on Monday. The company has a market capitalization of $405.13 million, a price-to-earnings ratio of -1.73 and a beta of 1.02. Atara Biotherapeutics, Inc. has a one year low of $2.83 and a one year high of $18.85. The stock has a 50-day simple moving average of $4.24 and a 200 day simple moving average of $4.86.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ATRA. Nisa Investment Advisors LLC increased its holdings in shares of Atara Biotherapeutics by 893.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 6,460 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 5,810 shares during the last quarter. Point72 Hong Kong Ltd increased its stake in Atara Biotherapeutics by 343.8% during the first quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 5,604 shares during the last quarter. US Bancorp DE raised its holdings in shares of Atara Biotherapeutics by 6,394.9% during the third quarter. US Bancorp DE now owns 7,664 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 7,546 shares during the period. Running Point Capital Advisors LLC bought a new position in shares of Atara Biotherapeutics in the 1st quarter worth about $93,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Atara Biotherapeutics in the 1st quarter valued at about $93,000.

Analyst Ratings Changes

ATRA has been the subject of several recent analyst reports. The Goldman Sachs Group dropped their target price on Atara Biotherapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a research report on Tuesday, August 9th. Mizuho dropped their price objective on Atara Biotherapeutics from $39.00 to $31.00 and set a “buy” rating on the stock in a report on Tuesday, August 16th. Finally, StockNews.com initiated coverage on Atara Biotherapeutics in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $18.71.

About Atara Biotherapeutics

(Get Rating)

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.

Further Reading

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.